Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
INLIGHT Phase 1 data continue to support WVE-007’s novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen
Covered in this story
Call it yourself
No calls on $WVE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Wave Life Sciences LTD →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.